Hereditary Angioedema Market to Discern Magnified Growth of 9.1% CAGR From 2017 to 2025 – Coherent Market Insights
SEATTLE, March 17, 2021, (PHARMIWEB) —
Hereditary Angioedema Market – Efficient Disease Management for Orphan Disease
Hereditary angioedema (HAE) is a rare disorder related to immune system. This life-threatening condition is caused due to the lack of C1-esterase inhibitor (C1-INH) that causes the blood vessels to dilate. The symptoms of the disease includes recurrent episodes of edema in various body parts such as hands, feet, face and airways. HAE is classified into 3 types: Type I HAE, Type II HAE, and Type III HAE based on the reduction in its synthesis of inhibitor or the formation of a dysfunctional protein. Although, the condition is hereditary, the absence of a family history does not rule out the diagnosis of HAE, indicating that as many as 25% of HAE cases result from a spontaneous mutation of the C1-inhibitor gene at conception.
Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1292
The global hereditary angioedema market was valued at US$ 1,563.7 million in 2016, and is expected to exhibit a CAGR of 9.1% over the forecast period (2017-2025).
Figure 1. Global Hereditary Angioedema Market (US$ Mn), by Region, 2016
Increasing prevalence and rising awareness of hereditary angioedema are expected to augment the market growth
Increasing number of hereditary angioedema cases is expected to propel market growth. For instance, according to a survey by the International Hereditary Angioedema Organization (HAEi), 2015, the global prevalence of hereditary angioedema is estimated to be around 1 in 10,000 to 50,000 people, which accounts a quarter million people suffer globally from this rare and life threatening deficiency condition. Moreover, according to the National Association for Rare Disorders, 2016, the risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child. North America is expected to hold dominant position in the hereditary angioedema market, owing to rising number of drug approvals in the regions, presence of major manufacturers, and presence of various organizations serving HAE patients. For instance, in 2017, the U.S. Food and Drug Administration (FDA) approved Haegarda (C1-esterase inhibitor) manufactured by CSL Behring for routine prophylaxis to prevent HAE attacks in adolescent and adult patients. However, rare occurrence of the disease make it difficult for efficient diagnosis and either opt for alternative therapies to control the disease, thus accounting to be the major factors restraining the market growth.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Quick Buy – Hereditary Angioedema Market Research Report: https://bit.ly/3bW2bkp
Increasing support from non-profit organizations towards intensive research is expected to accelerate the market
The organizations are focusing on increasing global HAE awareness by educating and empowering patient, providing access to suitable therapy/treatment. The organizations are also working towards intensive research to find a cure. For instance, the non-profit organization named HAEi is dedicated towards spreading awareness of C1-inhibitor deficiencies and to improve diagnosis, facilitating access to reimbursement of the HAE therapies, enabling lifelong health for the global patients. The organization also initiated the Global Access Program (HAEi GAP) in 2015, to provide access to the approved HAE medications in countries where modern therapies are otherwise unavailable. Moreover, the non-profit organization- US Hereditary Angioedema Association is committed to advance and conduct clinical research designed to improve the lives of HAE patients.
Major players operating in the global hereditary angioedema market include CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Attune Pharmaceuticals, Inc.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/significant-number-of-pipeline-drugs-to-surge-hereditary-angioedema-market-beyond-us-34-billion-by-2025-595
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Key Highlights
- Pipeline Analysis
- Regulatory Guidelines
- Epidemiology
- Market Dynamics
- Global Hereditary Angioedema Market, By Drug Class, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- C1 Esterase Inhibitor
- Kallikrein Inhibitor
- Bradykinin Receptor
- Attenuated Androgens
- Others
- Introduction
- Global Hereditary Angioedema Market, By Route of Administration, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Subcutaneous
- Intravenous
- Oral
- Introduction
- Global Hereditary Angioedema Market, By Distribution Channel, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Hospital Pharmacies
- Retail Pharmacies
- e-Commerce
- Introduction
- Global Hereditary Angioedema Market, By Region, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 – 2025
- North America
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of APAC
- Middle East
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3×3 Matrix)
- Company Profiles
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
